- Poster presentation
- Open Access
Docking based 3D-QSAR studies applied at the BRAF inhibitors to understand the binding mechanism
© Mahmood and ul-Haq; licensee BioMed Central Ltd. 2012
Published: 1 May 2012
B-RaF is a member of the RAF family of serine/threonine kinases involved in the regulation of cell growth, differentiation, and proliferation. It forms part of a conserved apoptosis signals through the RAS-RAF-MAPK pathway. As an important target of the cancer treatment B-Raf has more potential for researcher. The discovery of the V600EB-RAF mutation  has elevated expectation for targeted therapy against human melanoma. In the current work the molecular modeling study were carried out very first time with 3D-QSAR studies  by correlating the docking protocol for three different datasets of B-Raf inhibitors. Based on the co-crystallized compound (PDB ID: 1UWJ), several alignment methods were utilized to derive reliable CoMFA and CoMSIA models. The best CoMFA model (q2 =0.753, r2 =0.807). With the same alignment protocol, a statistically reliable CoMSIA model # 14 was also derived (q2 = 0.962, r2 = 0.961). The actual predictive powers of both models were thoroughly validated with an external test set, which gave satisfactory predictive r2 values of 0.89 and 0.90, respectively. Contour maps from CoMFA and CoMSIA models, supporting the statistical results and revealed important structural features responsible for increasing biological activity within the active site and explained the correlation between biological activity and receptor-ligand interactions. These results can offer useful information for the design of new B-Raf inhibitor.
- Davies H, Bignell GR, Bottomley W: Mutations of the BRAF Gene in Human Cancer. Nature. 417: 949-954.Google Scholar
- Ul-Haq Z, Mahmood U, Jehangir B: Ligand-based 3D-QSAR Studies of Physostigmine Analogues as Acetylcholinesterase Inhibitors. Chem Biol Drug Des. 2009, 74: 571-581. 10.1111/j.1747-0285.2009.00897.x.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.